Pactiv Evergreen (PTVE) announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 in connection with the Company’s previously announced definitive agreement to be acquired by Novolex for $18.00 per share in cash. The transaction is expected to close in the second quarter of 2025, subject to receipt of foreign antitrust approvals and satisfaction of other customary closing conditions. Upon the completion of the transaction, Pactiv Evergreen will become a privately held company, and its common stock will no longer be listed on Nasdaq.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTVE:
- Pactiv Evergreen downgraded to Neutral from Buy at UBS
- Pactiv Evergreen downgraded to Sector Perform from Outperform at RBC Capital
- Pactiv Evergreen downgraded to Hold from Buy at Jefferies
- Pactiv Evergreen price target raised to $18 from $12 at Baird
- BofA moves to No Rating on Pactiv Evergreen after Novolex deal
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue